Sign inJoin waitlistJoin the waitlist

AM

Alison Moskowitz

Associate Attending Physician · New York Presbyterian Hospital

Credentials: · · ·

History

Memorial Sloan Kettering Westchester
2023–Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2006–2009
Columbia University Medical Center
2003–2006
Albert Einstein College of Medicine
1999–2003

Research

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology · 2018 · 552 citations
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers
Review · Journal of the American Academy of Dermatology · 2014 · 295 citations
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Blood · 2018 · 259 citations

SH
Steven Horwitz
110 papers
AZ
Andrew Zelenetz
51 papers
AN
Ariela Noy
48 papers
AK
Anita Kumar
46 papers
PH
Paul Hamlin
46 papers
Craig Moskowitz
40 papers
Matthew Matasar
38 papers
Lia Palomba
37 papers
AD
Ahmet Dogan
36 papers
DS
David Straus
34 papers
PM
Patricia Myskowski
34 papers
Heiko Schöder
28 papers

Clinical trials

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2027
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2021–2027
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2018–2026
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2018–2027